drugset / Trial / NCT01071135

Quetiapine XR in Schizophrenic Patients

NCT01071135

Phase 3 Terminated 5 enrolled Hannover Medical School AstraZeneca · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to determine the effect of Quetiapine in patients with schizophrenia induced by cannabis abuse.

Timeline

Start
2009-09
Primary completion
2010-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 400 mg Oral
Subject Quetiapine Small molecule 800 mg Oral

Indications